AD5-nCOV, trade-named Convidecia, is a single-dose viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino...
37 KB (3,397 words) - 07:19, 24 September 2024
Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi–GSK. Seven others are under assessment by the WHO: Sputnik...
322 KB (19,558 words) - 03:33, 16 September 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
369 KB (32,754 words) - 03:35, 17 November 2024
vaccines were two-dose vaccines, with the exception single-dose vaccines Convidecia and the Janssen COVID‑19 vaccine, and vaccines with three-dose schedules...
206 KB (23,339 words) - 12:10, 20 November 2024
vaccines were two-dose vaccines, with the exception single-dose vaccines Convidecia and the Janssen COVID‑19 vaccine, and vaccines with three-dose schedules...
288 KB (33,185 words) - 21:10, 15 November 2024
Products Administration granted approval for the Convidecia Air, an inhaled version of the Convidecia vaccine, to be used as a booster dose. China - In...
8 KB (635 words) - 06:53, 20 November 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
21 KB (763 words) - 21:21, 15 November 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
18 KB (1,606 words) - 21:29, 2 November 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
351 KB (385 words) - 12:39, 16 November 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
72 KB (15,187 words) - 22:02, 12 September 2024
Vaccines using other technologies would not be affected, but Sputnik V, Convidecia and ImmunityBio's hAd5 would. Two studies found that Ad5-specific CD4...
49 KB (5,559 words) - 18:51, 11 October 2024
which had cancelled CanSino's contract with Canada for its COVID vaccine, Convidecia. Poilievre insisted that Canada should create its own vaccines supply...
198 KB (16,917 words) - 10:34, 16 November 2024
later worked together to develop an Ebola vaccine. AD5-nCOV, trade-named Convidecia, is a single-dose viral vector COVID-19 vaccine developed by CanSino....
15 KB (1,099 words) - 19:03, 12 September 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
125 KB (9,866 words) - 01:21, 18 September 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
13 KB (1,536 words) - 14:46, 18 October 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
173 KB (16,236 words) - 06:58, 20 November 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
122 KB (12,462 words) - 03:40, 15 August 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
81 KB (8,339 words) - 05:29, 11 November 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
71 KB (5,872 words) - 05:25, 14 November 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
117 KB (13,528 words) - 20:58, 27 October 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
219 KB (25,000 words) - 21:34, 25 October 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
185 KB (15,899 words) - 08:16, 8 November 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
204 KB (18,016 words) - 04:55, 14 November 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
260 KB (22,097 words) - 23:43, 14 October 2024
COVID-19 pandemic, the AMMS partnered with CanSino Biologics to develop Convidecia. The development team, led by Chen Wei, registered a Phase 1 trial in...
12 KB (1,008 words) - 18:05, 12 September 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
375 KB (33,063 words) - 01:40, 26 October 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
3 KB (157 words) - 10:20, 24 September 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
58 KB (6,693 words) - 06:16, 14 November 2024
US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm...
122 KB (11,033 words) - 06:12, 17 November 2024
Academy of Military Medical Sciences, and CanSino Biologics to develop Convidecia. The development team registered a Phase 1 trial in March 2020 and a Phase...
15 KB (1,083 words) - 19:10, 12 September 2024